Your browser doesn't support javascript.
loading
Targeting Wnt-ß-Catenin-FOSL Signaling Ameliorates Right Ventricular Remodeling.
Nayakanti, Sreenath Reddy; Friedrich, Aleksandra; Sarode, Poonam; Jafari, Leili; Maroli, Giovanni; Boehm, Mario; Bourgeois, Alice; Grobs, Yann; Khassafi, Fatemeh; Kuenne, Carsten; Guenther, Stefan; Dabral, Swati; Wilhelm, Jochen; Weiss, Astrid; Wietelmann, Astrid; Kojonazarov, Baktybek; Janssen, Wiebke; Looso, Mario; de Man, Frances; Provencher, Steeve; Tello, Khodr; Seeger, Werner; Bonnet, Sebastien; Savai, Rajkumar; Schermuly, Ralph T; Pullamsetti, Soni Savai.
Afiliación
  • Nayakanti SR; Max-Planck Institute for Heart and Lung Research, Bad Nauheim, Germany (S.R.N., A.F., P.S., L.J., G.M., F.K., C.K., S.G., S.D., W.J., M.L., W.S., R.S., S.S.P.).
  • Friedrich A; Department of Internal Medicine, Member of the DZL, Member of CPI, Justus Liebig University, Giessen, Germany (S.R.N., L.J., G.M., M.B., A. Weiss, B.K., K.T., W.S., R.S., R.T.S., S.S.P.).
  • Sarode P; Max-Planck Institute for Heart and Lung Research, Bad Nauheim, Germany (S.R.N., A.F., P.S., L.J., G.M., F.K., C.K., S.G., S.D., W.J., M.L., W.S., R.S., S.S.P.).
  • Jafari L; Max-Planck Institute for Heart and Lung Research, Bad Nauheim, Germany (S.R.N., A.F., P.S., L.J., G.M., F.K., C.K., S.G., S.D., W.J., M.L., W.S., R.S., S.S.P.).
  • Maroli G; Institute for Lung Health (ILH), Member of the DZL, Justus Liebig University, Giessen, Germany (P.S., J.W., B.K., W.S., R.S., S.S.P).
  • Boehm M; Max-Planck Institute for Heart and Lung Research, Bad Nauheim, Germany (S.R.N., A.F., P.S., L.J., G.M., F.K., C.K., S.G., S.D., W.J., M.L., W.S., R.S., S.S.P.).
  • Bourgeois A; Department of Internal Medicine, Member of the DZL, Member of CPI, Justus Liebig University, Giessen, Germany (S.R.N., L.J., G.M., M.B., A. Weiss, B.K., K.T., W.S., R.S., R.T.S., S.S.P.).
  • Grobs Y; Max-Planck Institute for Heart and Lung Research, Bad Nauheim, Germany (S.R.N., A.F., P.S., L.J., G.M., F.K., C.K., S.G., S.D., W.J., M.L., W.S., R.S., S.S.P.).
  • Khassafi F; Department of Internal Medicine, Member of the DZL, Member of CPI, Justus Liebig University, Giessen, Germany (S.R.N., L.J., G.M., M.B., A. Weiss, B.K., K.T., W.S., R.S., R.T.S., S.S.P.).
  • Kuenne C; Department of Internal Medicine, Member of the DZL, Member of CPI, Justus Liebig University, Giessen, Germany (S.R.N., L.J., G.M., M.B., A. Weiss, B.K., K.T., W.S., R.S., R.T.S., S.S.P.).
  • Guenther S; Pulmonary Hypertension Research Group, CRIUCPQ - Research center of the Quebec Heart and Lung Institute, Department of Medicine, Université Laval, Québec, QC, Canada (A.B., Y.G., S.P., S.B.).
  • Dabral S; Pulmonary Hypertension Research Group, CRIUCPQ - Research center of the Quebec Heart and Lung Institute, Department of Medicine, Université Laval, Québec, QC, Canada (A.B., Y.G., S.P., S.B.).
  • Wilhelm J; Max-Planck Institute for Heart and Lung Research, Bad Nauheim, Germany (S.R.N., A.F., P.S., L.J., G.M., F.K., C.K., S.G., S.D., W.J., M.L., W.S., R.S., S.S.P.).
  • Weiss A; Max-Planck Institute for Heart and Lung Research, Bad Nauheim, Germany (S.R.N., A.F., P.S., L.J., G.M., F.K., C.K., S.G., S.D., W.J., M.L., W.S., R.S., S.S.P.).
  • Wietelmann A; Max-Planck Institute for Heart and Lung Research, Bad Nauheim, Germany (S.R.N., A.F., P.S., L.J., G.M., F.K., C.K., S.G., S.D., W.J., M.L., W.S., R.S., S.S.P.).
  • Kojonazarov B; Max-Planck Institute for Heart and Lung Research, Bad Nauheim, Germany (S.R.N., A.F., P.S., L.J., G.M., F.K., C.K., S.G., S.D., W.J., M.L., W.S., R.S., S.S.P.).
  • Janssen W; Institute for Lung Health (ILH), Member of the DZL, Justus Liebig University, Giessen, Germany (P.S., J.W., B.K., W.S., R.S., S.S.P).
  • Looso M; Department of Internal Medicine, Member of the DZL, Member of CPI, Justus Liebig University, Giessen, Germany (S.R.N., L.J., G.M., M.B., A. Weiss, B.K., K.T., W.S., R.S., R.T.S., S.S.P.).
  • de Man F; Scientific Service Group MRI and µ-CT, Max Planck Institute for Heart and Lung Research, Bad Nauheim, Germany (A. Wietelmann).
  • Provencher S; Department of Internal Medicine, Member of the DZL, Member of CPI, Justus Liebig University, Giessen, Germany (S.R.N., L.J., G.M., M.B., A. Weiss, B.K., K.T., W.S., R.S., R.T.S., S.S.P.).
  • Tello K; Institute for Lung Health (ILH), Member of the DZL, Justus Liebig University, Giessen, Germany (P.S., J.W., B.K., W.S., R.S., S.S.P).
  • Seeger W; Max-Planck Institute for Heart and Lung Research, Bad Nauheim, Germany (S.R.N., A.F., P.S., L.J., G.M., F.K., C.K., S.G., S.D., W.J., M.L., W.S., R.S., S.S.P.).
  • Bonnet S; Max-Planck Institute for Heart and Lung Research, Bad Nauheim, Germany (S.R.N., A.F., P.S., L.J., G.M., F.K., C.K., S.G., S.D., W.J., M.L., W.S., R.S., S.S.P.).
  • Savai R; Department of Pulmonary Medicine, PHEniX Laboratory, Amsterdam Cardiovascular Sciences, Vrije Universiteit, Amsterdam, the Netherlands (F.d.M.).
  • Schermuly RT; Pulmonary Hypertension Research Group, CRIUCPQ - Research center of the Quebec Heart and Lung Institute, Department of Medicine, Université Laval, Québec, QC, Canada (A.B., Y.G., S.P., S.B.).
  • Pullamsetti SS; Department of Internal Medicine, Member of the DZL, Member of CPI, Justus Liebig University, Giessen, Germany (S.R.N., L.J., G.M., M.B., A. Weiss, B.K., K.T., W.S., R.S., R.T.S., S.S.P.).
Circ Res ; 132(11): 1468-1485, 2023 05 26.
Article en En | MEDLINE | ID: mdl-37042252
ABSTRACT

BACKGROUND:

The ability of the right ventricle (RV) to adapt to an increased pressure afterload determines survival in patients with pulmonary arterial hypertension. At present, there are no specific treatments available to prevent RV failure, except for heart/lung transplantation. The wingless/int-1 (Wnt) signaling pathway plays an important role in the development of the RV and may also be implicated in adult cardiac remodeling.

METHODS:

Molecular, biochemical, and pharmacological approaches were used both in vitro and in vivo to investigate the role of Wnt signaling in RV remodeling.

RESULTS:

Wnt/ß-catenin signaling molecules are upregulated in RV of patients with pulmonary arterial hypertension and animal models of RV overload (pulmonary artery banding-induced and monocrotaline rat models). Activation of Wnt/ß-catenin signaling leads to RV remodeling via transcriptional activation of FOSL1 and FOSL2 (FOS proto-oncogene [FOS] like 1/2, AP-1 [activator protein 1] transcription factor subunit). Immunohistochemical analysis of pulmonary artery banding -exposed BAT-Gal (ß-catenin-activated transgene driving expression of nuclear ß-galactosidase) reporter mice RVs exhibited an increase in ß-catenin expression compared with their respective controls. Genetic inhibition of ß-catenin, FOSL1/2, or WNT3A stimulation of RV fibroblasts significantly reduced collagen synthesis and other remodeling genes. Importantly, pharmacological inhibition of Wnt signaling using inhibitor of PORCN (porcupine O-acyltransferase), LGKK-974 attenuated fibrosis and cardiac hypertrophy leading to improvement in RV function in both, pulmonary artery banding - and monocrotaline-induced RV overload.

CONCLUSIONS:

Wnt- ß-Catenin-FOSL signaling is centrally involved in the hypertrophic RV response to increased afterload, offering novel targets for therapeutic interference with RV failure in pulmonary hypertension.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Hipertensión Arterial Pulmonar / Insuficiencia Cardíaca Tipo de estudio: Prognostic_studies Límite: Animals Idioma: En Revista: Circ Res Año: 2023 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Hipertensión Arterial Pulmonar / Insuficiencia Cardíaca Tipo de estudio: Prognostic_studies Límite: Animals Idioma: En Revista: Circ Res Año: 2023 Tipo del documento: Article